Skip to main content
Erschienen in: Cancer and Metastasis Reviews 1/2012

01.09.2012

The role of pharmacogenomics in metastatic renal cell carcinoma

verfasst von: Daniel Castellano, Juan Antonio Virizuela, Josefina Cruz, Juan Manuel Sepulveda, Maribel Sáenz, Luís Paz-Ares

Erschienen in: Cancer and Metastasis Reviews | Sonderheft 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Pharmacogenomics is the study of how variation in the genetic background affects an individual’s response to a specific drug and/or its metabolism. Using knowledge about the genes which produce the enzymes that metabolize a specific drug, a physician may decide to raise or lower the dose, or even change to a different drug. Targeted therapy with tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors has led to a substantial improvement in the standard of care for patients with advanced or metastatic renal cell carcinoma (RCC). Although few studies have identified biomarkers that predict the response of targeted drugs in the treatment of metastatic RCC, some associations have been found. Several studies have identified genetic polymorphisms with implications in the pharmacokinetics and/or pharmacodynamics of TKIs and mTOR inhibitors and which are associated with a prolonged progression-free survival and/or overall survival in patients with metastatic RCC. Among the genes of interest, we should consider IL8, FGFR2, VEGFA, FLT4, and NR1I2. In this review, we discuss single nucleotide polymorphisms (SNPs) associated with outcome and toxicity following targeted therapies and provide recommendations for future trials to facilitate the use of SNPs in personalized therapy for this disease.
Literatur
1.
Zurück zum Zitat Ingelman-Sundberg, M. (2001). Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. Journal of Internal Medicine, 250, 186–200.PubMedCrossRef Ingelman-Sundberg, M. (2001). Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. Journal of Internal Medicine, 250, 186–200.PubMedCrossRef
2.
Zurück zum Zitat Evans, W. E., & Johnson, J. A. (2001). Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annual Review of Genomics and Human Genetics, 2, 9–39.PubMedCrossRef Evans, W. E., & Johnson, J. A. (2001). Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annual Review of Genomics and Human Genetics, 2, 9–39.PubMedCrossRef
5.
Zurück zum Zitat Belle, D. J., & Singh, H. (2008). Genetic factors in drug metabolism. American Family Physician, 77, 1553–1560.PubMed Belle, D. J., & Singh, H. (2008). Genetic factors in drug metabolism. American Family Physician, 77, 1553–1560.PubMed
6.
Zurück zum Zitat Giacomini, K. M., Brett, C. M., Altman, R. B., et al. (2007). The pharmacogenetics research network: from SNP discovery to clinical drug response. Clinical Pharmacology and Therapeutics, 81, 328–345.PubMedCrossRef Giacomini, K. M., Brett, C. M., Altman, R. B., et al. (2007). The pharmacogenetics research network: from SNP discovery to clinical drug response. Clinical Pharmacology and Therapeutics, 81, 328–345.PubMedCrossRef
7.
Zurück zum Zitat van Erp, N. P., Eechoute, K., van der Veldt, A. A., et al. (2009). Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. Journal of Clinical Oncology, 27, 4406–4412.PubMedCrossRef van Erp, N. P., Eechoute, K., van der Veldt, A. A., et al. (2009). Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. Journal of Clinical Oncology, 27, 4406–4412.PubMedCrossRef
8.
Zurück zum Zitat Shukla, S., Robey, R. W., Bates, S. E., et al. (2009). Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metabolism and Disposition, 37, 359–365.PubMedCrossRef Shukla, S., Robey, R. W., Bates, S. E., et al. (2009). Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metabolism and Disposition, 37, 359–365.PubMedCrossRef
9.
Zurück zum Zitat Xu, C. F., Reck, B. H., Goodman, V. L., et al. (2011). Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. Journal of Hepatology, 54, 1237–1243.PubMedCrossRef Xu, C. F., Reck, B. H., Goodman, V. L., et al. (2011). Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. Journal of Hepatology, 54, 1237–1243.PubMedCrossRef
10.
Zurück zum Zitat Tran, H. T., Liu, Y., Lin, Y., et al. (2010). Use of a multiplatform analysis of plasma cytokines and angiogenic factors (CAFs) to identify baseline CAFs associated with pazopanib response and tumor burden in renal cell carcinoma (RCC) patients. Journal of Clinical Oncology, 28(15s (Abstr 4522)). Tran, H. T., Liu, Y., Lin, Y., et al. (2010). Use of a multiplatform analysis of plasma cytokines and angiogenic factors (CAFs) to identify baseline CAFs associated with pazopanib response and tumor burden in renal cell carcinoma (RCC) patients. Journal of Clinical Oncology, 28(15s (Abstr 4522)).
11.
Zurück zum Zitat Staehler, M., Rohrmann, K., Haseke, N., et al. (2005). Targeted agents for the treatment of advanced renal cell carcinoma. Current Drug Targets, 6, 835–846.PubMedCrossRef Staehler, M., Rohrmann, K., Haseke, N., et al. (2005). Targeted agents for the treatment of advanced renal cell carcinoma. Current Drug Targets, 6, 835–846.PubMedCrossRef
12.
Zurück zum Zitat Vogelzang, N. J. (2006). Treatment options in metastatic renal carcinoma: an embarrassment of riches. Journal of Clinical Oncology, 24, 1–3.PubMedCrossRef Vogelzang, N. J. (2006). Treatment options in metastatic renal carcinoma: an embarrassment of riches. Journal of Clinical Oncology, 24, 1–3.PubMedCrossRef
13.
Zurück zum Zitat Vaziri, S. A., Kim, J., Ganapathi, M. K., et al. (2010). Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors. Current Oncology Reports, 12, 102–108.PubMedCrossRef Vaziri, S. A., Kim, J., Ganapathi, M. K., et al. (2010). Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors. Current Oncology Reports, 12, 102–108.PubMedCrossRef
14.
Zurück zum Zitat Ball, H. A., Xu, C. & Sternberg, C. N. et al. (2010) Association of germ-line genetic markers in IL8, HIF1A, VEGFA, and VEGFR2 with treatment response to pazopanib in renal cell carcinoma. In: ASCO Meeting Abstracts 28, p. 4520. Ball, H. A., Xu, C. & Sternberg, C. N. et al. (2010) Association of germ-line genetic markers in IL8, HIF1A, VEGFA, and VEGFR2 with treatment response to pazopanib in renal cell carcinoma. In: ASCO Meeting Abstracts 28, p. 4520.
15.
Zurück zum Zitat Xu, C., Ball, H. A., Bing, N., et al. (2011). Association of genetic markers in angiogenesis- or exposure-related genes with overall survival in pazopanib (P) treated patients (Pts) with advanced renal cell carcinoma. ASCO Meeting Abstracts, 29, 303. Xu, C., Ball, H. A., Bing, N., et al. (2011). Association of genetic markers in angiogenesis- or exposure-related genes with overall survival in pazopanib (P) treated patients (Pts) with advanced renal cell carcinoma. ASCO Meeting Abstracts, 29, 303.
16.
Zurück zum Zitat Garcia-Donas, J., Esteban, E., Leandro-Garcia, L. J., et al. (2011). Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. The Lancet Oncology, 12, 1143–1150.PubMedCrossRef Garcia-Donas, J., Esteban, E., Leandro-Garcia, L. J., et al. (2011). Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. The Lancet Oncology, 12, 1143–1150.PubMedCrossRef
17.
Zurück zum Zitat van der Veldt, A. A., Eechoute, K., Gelderblom, H., et al. (2011). Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clinical Cancer Research, 17, 620–629.PubMedCrossRef van der Veldt, A. A., Eechoute, K., Gelderblom, H., et al. (2011). Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clinical Cancer Research, 17, 620–629.PubMedCrossRef
18.
Zurück zum Zitat Swanton, C., Larkin, J. M., Gerlinger, M., et al. (2010). Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. Genome Medicine, 2, 53.PubMedCrossRef Swanton, C., Larkin, J. M., Gerlinger, M., et al. (2010). Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. Genome Medicine, 2, 53.PubMedCrossRef
Metadaten
Titel
The role of pharmacogenomics in metastatic renal cell carcinoma
verfasst von
Daniel Castellano
Juan Antonio Virizuela
Josefina Cruz
Juan Manuel Sepulveda
Maribel Sáenz
Luís Paz-Ares
Publikationsdatum
01.09.2012
Verlag
Springer US
Erschienen in
Cancer and Metastasis Reviews / Ausgabe Sonderheft 1/2012
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-012-9356-x

Weitere Artikel der Sonderheft 1/2012

Cancer and Metastasis Reviews 1/2012 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.